HUP0102142A2 - Ciklosporinok alkalmazása gyulladással járó autoimmun betegségek kezelésében - Google Patents

Ciklosporinok alkalmazása gyulladással járó autoimmun betegségek kezelésében

Info

Publication number
HUP0102142A2
HUP0102142A2 HU0102142A HUP0102142A HUP0102142A2 HU P0102142 A2 HUP0102142 A2 HU P0102142A2 HU 0102142 A HU0102142 A HU 0102142A HU P0102142 A HUP0102142 A HU P0102142A HU P0102142 A2 HUP0102142 A2 HU P0102142A2
Authority
HU
Hungary
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
cyclophilin
Prior art date
Application number
HU0102142A
Other languages
English (en)
Inventor
Peter Hiestand
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0102142A2 publication Critical patent/HUP0102142A2/hu
Publication of HUP0102142A3 publication Critical patent/HUP0102142A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A jelen találmány a ciklosporinok új alkalmazásaira vonatkozik,különösen a nem-immunszuppresszív, ciklofilinhez kötődő ciklosporinokúj gyógyászati alkalmazásaira. A nem-immunszuppresszív, ciklofilinhezkötődő ciklosporinok, különösen a[MeIle]4-Ciklosporin,felhasználhatók gyulladással járó autoimmun betegségek, mint pl.rheumatoid arthritis kezelésében és megelőzésében. Ó
HU0102142A 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases HUP0102142A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (2)

Publication Number Publication Date
HUP0102142A2 true HUP0102142A2 (hu) 2001-11-28
HUP0102142A3 HUP0102142A3 (en) 2001-12-28

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102142A HUP0102142A3 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (hu)
JP (2) JP4523154B2 (hu)
KR (1) KR20010043969A (hu)
CN (1) CN1304315A (hu)
AU (1) AU750422B2 (hu)
BR (1) BR9910860A (hu)
CA (1) CA2333315A1 (hu)
GB (1) GB9811854D0 (hu)
HU (1) HUP0102142A3 (hu)
ID (1) ID27576A (hu)
IL (1) IL139589A0 (hu)
NO (1) NO20006113L (hu)
PL (1) PL344451A1 (hu)
SK (1) SK18142000A3 (hu)
TW (2) TWI250021B (hu)
WO (1) WO1999062540A1 (hu)
ZA (1) ZA200006464B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
AU2001291579B2 (en) * 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
RU2006139004A (ru) * 2004-04-08 2008-05-20 Новартис АГ (CH) Применение циклоспоринов для лечения церебральной ишемии и повреждения головного и спинного мозга
RU2394589C2 (ru) 2004-07-14 2010-07-20 Новартис Аг Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
EP1793844B1 (en) * 2004-10-01 2010-12-08 Debiopharm S.A. Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
NZ555142A (en) * 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
MX2007007779A (es) * 2004-12-23 2007-08-14 Novartis Ag Composiciones para el tratamiento de infeccion de hepatitis c.
JP2008546708A (ja) * 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
JP2007112775A (ja) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
WO2010002428A2 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
US20110144005A1 (en) * 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
CN104603146B (zh) 2012-09-29 2018-01-02 诺华股份有限公司 环肽类化合物及其作为药物的用途
US20140213508A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Antiviral macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124459T3 (de) * 1990-11-02 2001-05-31 Novartis Ag Zyklosporine
AR006514A1 (es) * 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
CZ288631B6 (cs) * 1996-01-18 2001-08-15 Galena, A. S. Léčivé přípravky s obsahem cyklosporinu
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
JP2002516873A (ja) 2002-06-11
KR20010043969A (ko) 2001-05-25
BR9910860A (pt) 2001-03-06
IL139589A0 (en) 2002-02-10
EP1082130A1 (en) 2001-03-14
JP2010059177A (ja) 2010-03-18
AU750422B2 (en) 2002-07-18
NO20006113D0 (no) 2000-12-01
SK18142000A3 (sk) 2001-06-11
NO20006113L (no) 2001-01-25
ZA200006464B (en) 2002-03-11
TWI250022B (en) 2006-03-01
CA2333315A1 (en) 1999-12-09
CN1304315A (zh) 2001-07-18
HUP0102142A3 (en) 2001-12-28
AU4372499A (en) 1999-12-20
ID27576A (id) 2001-04-12
PL344451A1 (en) 2001-11-05
GB9811854D0 (en) 1998-07-29
WO1999062540A1 (en) 1999-12-09
JP4523154B2 (ja) 2010-08-11
TW200522975A (en) 2005-07-16
TWI250021B (en) 2006-03-01

Similar Documents

Publication Publication Date Title
HUP0102142A2 (hu) Ciklosporinok alkalmazása gyulladással járó autoimmun betegségek kezelésében
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
MY134806A (en) Cyclosporins
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
NZ333657A (en) A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
EP1329458A3 (en) Peptides that lower blood glucose levels
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
AU8918998A (en) Non-immunosuppressive cyclosporins and their use in the prevention and treatmentof hiv infection
FR2774588B1 (fr) Composition cosmetique ou dermatologique contenant au moins une proteine de soie d'arachnides naturelle, recombinante ou un analogue
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
ATE204297T1 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
NZ508956A (en) Conformationally constrained backbone cyclized somatostatin analogs
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
AU2001292843A1 (en) Crystal structure of bace and uses thereof
CA2139725A1 (en) Endoparasiticidal compositions
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
EP0830130A4 (en) TNF-ALPHA CONVERTING ENZYME
IL158385A0 (en) Modified cyclosporin which can be used as a pro-drug and use thereof
AU6682594A (en) Treatment of septic shock
WO2001045650A3 (de) Kosmetische verwendung von rückständen aus der weinherstellung
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
ZA974366B (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.
HK1029099A1 (en) 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
WO2003024474A3 (en) Anti-inflammatory agent